The treatment of glioblastoma remains a major challenge in the field of neuro-oncology. There is emerging evidence that glioblastomas consist of heterogeneous cell populations with a small subset of cells with stem cell-like properties which might be resistant to conventional therapy and are thus crucial for tumor recurrence. These glioma-initiating cells (GICs) are therefore an attractive therapeutic target. Death receptor activation is one promising approach of cancer therapy. The synthetic hexameric cluster of differentiation 95 (CD95) agonist APO010 exhibits strong antiglioma activity towards human glioma cell lines, as well as in cell cultures of primary glioblastoma. Here, we investigated the ability of APO010 to induce cell death in a panel of previously well-defined GIC lines. The GIC lines and their derived differentiated cultures expressed CD95 on the cell surface and were sensitive towards APO010-mediated cell death to a variable extent. Temozolomide enhanced sensitivity of GICs to APO010. APO010 warrants being further evaluated as a tool to target GICs.

译文

胶质母细胞瘤的治疗仍然是神经肿瘤学领域的主要挑战。有新的证据表明,胶质母细胞瘤由异质细胞群组成,其中一小部分具有干细胞样特性的细胞亚群可能对常规疗法具有抵抗力,因此对肿瘤复发至关重要。因此,这些神经胶质瘤起始细胞 (gic) 是有吸引力的治疗靶标。死亡受体激活是一种有前途的癌症治疗方法。合成的六聚体分化簇95 (CD95) 激动剂APO010对人神经胶质瘤细胞系以及原发性胶质母细胞瘤的细胞培养物表现出很强的抗神经胶质瘤活性。在这里,我们研究了APO010在一组先前定义明确的GIC系中诱导细胞死亡的能力。GIC系及其衍生的分化培养物在细胞表面表达CD95,并在不同程度上对APO010-mediated细胞死亡敏感。替莫唑胺增强了GICs对apo010的敏感性。APO010认股权证被进一步评估为针对gic的工具。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录